JMP Securities analyst Jason Butler reiterated a Buy rating on Quoin Pharmaceuticals (QNRX – Research Report) today and set a price target of $8.00. The company’s shares closed last Thursday at $0.36, close to its 52-week low of $0.32.
According to TipRanks.com, Butler is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -7.8% and a 40.5% success rate. Butler covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Aquestive Therapeutics, and ACADIA Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Quoin Pharmaceuticals with a $5.00 average price target.
See today’s best-performing stocks on TipRanks >>
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. Cellect Biotechnology was founded by Kasbian Nuriel Chirich, Shai Yarkoni and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel.
Read More on QNRX:
- Rosenblatt Securities Keeps Their Hold Rating on Comcast (CMCSA)
- NORTHEAST INDIANA BANCORP, INC. ANNOUNCES CASH DIVIDEND
- Ohio Valley Banc Corp. Reports 2nd Quarter Earnings
- Update: Small Business Development Group (OTC: SBDG) Acquires Ubun2Group to Drive Revenue and Build Out AI Driven M&A Platforms; SBDG Details Success of its Business Plan
- Peoples Ltd. Announces Second Quarter Results
